Invivyd's pemivibart shows 84% relative risk reduction in symptomatic COVID-19 in Phase 3 exploratory analysis

Invivyd, Inc.

84% relative risk reduction vs placebo (1.9% vs 11.9% symptomatic COVID-19 rate, p=0.000061) over 180 days in immunocompetent cohort.
Immunocompromised cohort: 3% symptomatic COVID-19 rate; no COVID-19 hospitalizations or deaths over 180 days.
Safety: anaphylaxis in 0.6% of immunocompromised cohort (2 life-threatening); infusion reactions generally mild-moderate.
FDA updated PEMGARDA Fact Sheet for Healthcare Providers to include 180-day exploratory efficacy data.
Data collected during XBB/JN.1 variant waves; company to host conference call at 8:30AM EDT today.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.